Lyell Immunopharma Inc. (NASDAQ:LYEL) currently has a daily average trading volume of 1.05M but it saw 969524 shares traded on Wednesday. With a market cap of 658.63M USD, stock’s current market price of $2.89 came rising about 0.35 while comparing to the previous closing price of $2.88. In past 52 weeks, the stock remained buoying in the range of price level as high as $8.74 and as low as $1.77. In the recent trading on the day, stock has struck highest price mark of $2.935 while lowest mark touched by it was $2.70.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Taking a look at 20-day trading activity of Lyell Immunopharma Inc. (LYEL) gives us an average price of $2.51, while its current price level is -66.93% below from 52-week high level whereas it is 63.28% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.40 while that of 200 days or SMA-200 reads an average of $4.23. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.17% during that period while stretching the period over a month that increases to 10.03%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 59.67 which implies that the stock is in neutral territory.
Lyell Immunopharma Inc. (LYEL)’s stock is currently under the radar of 4 analysts who are in consensus at a 12-month price target range of between $4.00 and $10.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $4.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $10.00. Average price target assigned by them is $7.25 which highlights an upside potential of 60.14% for the stock over that period. And to attain the median price target of $7.50 assigned by those analysts, stock has to add about 61.47% of value to its current levels.
Data by FactSet Research shows that 4 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 2 analysts suggested the investors to Buy the stock while 2 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Overweight for the stock and that issued by Wall Street to investors is Moderate Buy.
Over the week, LYEL’s stock price is moving 8.24% up while it is 49.74% when we observe its performance for the past one month. Year-to-date it is -16.71% down and over the past year, the stock is showing a downside performance of -32.48%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$0.23 beat the consensus estimate of -$0.28 for the same. The company is expected to be releasing its next quarterly report in 08/10/2023, for which analysts forecasted an EPS of -$0.27 while estimate for next year EPS is -$1.15. For LYEL, analysts are forecasting an EPS-growth rate of -53.30% for current year and estimate for EPS growth in next year is -19.10%.
Currently, Lyell Immunopharma Inc.’s total number of outstanding shares is 249.59M with 15.72% of that held by the insiders while 68.19% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -23.00% and return on equity (ROE) at -22.00%. Stock has a price to book (P/B) ratio of 0.92 while price to sale or P/S ratio amounts to 7.82. Its return on asset (ROA) is -19.10% on average.
A filing at the U.S. Securities and Exchange Commission revealed that SPDR S&P Biotech ETF came shrinking its share ownership by 1.78% in the Lyell Immunopharma Inc. (LYEL) increasing its stake to 1.75% with control over 76285.0 shares in the company. In the most recent quarter, iShares Russell 2000 ETF came cutting its stake by -1.44% in the company and now holds 3.64 million or 1.46% of the company’s stake having worth of about 7.39 million.
Leave a Reply